Guidance for industry on implementing Shortage Prevention Plans (SPP)

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Hyftor, sirolimus, Date of authorisation: 15/05/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tenkasi (previously Orbactiv), oritavancin, Date of authorisation: 19/03/2015, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Docetaxel Kabi, docetaxel, Date of authorisation: 22/05/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Synjardy, empagliflozin,metformin, Date of authorisation: 27/05/2015, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Thiotepa Riemser, thiotepa, Date of authorisation: 26/03/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Date of authorisation: 20/02/2014, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Cholib, fenofibrate,simvastatin, Date of authorisation: 26/08/2013, Revision: 19, Status: Authorised